Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: Jul 19, 2026

In vitro Method to Observe E-selectin-mediated Interactions Between Prostate Circulating Tumor Cells Derived From Patients and Human Endothelial Cells

In vitro Method to Observe E-selectin-mediated Interactions Between Prostate Circulating Tumor Cells Derived From Patients and Human Endothelial Cells

Published on: May 15, 2014

Platelet function after single [153Sm]EDTMP therapy in prostate cancer.

K Weiss¹, B Palumbo, I Palumbo

¹Department of Nuclear Medicine, Hospital Wr. Neustadt, Austria.

The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of

|October 18, 2006

Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Yellow mealworm: effects of adults breeding density on adults and larvae performances from an industrial perspective.

Animal : an international journal of animal bioscience·2024

Same author

Right putamen and age are the most discriminant features to diagnose Parkinson's disease by using <sup>123</sup>I-FP-CIT brain SPET data by using an artificial neural network classifier, a classification tree (ClT).

Hellenic journal of nuclear medicine·2018

Same author

Brain natriuretic peptide as a cardiac marker of transient radiotherapy-related damage in left-sided breast cancer patients: A prospective study.

Breast (Edinburgh, Scotland)·2015

Same author

Periodontal healing after 'orthodontic extraction' of mandibular third molars: a retrospective cohort study.

International journal of oral and maxillofacial surgery·2014

Same author

The Vienna protocol and perspectives in radionuclide therapy.

The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...·2011

Same author

Relationship between PET-FDG and MRI apparent diffusion coefficients in brain tumors.

The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...·2008

Low-dose [153Sm] EDTMP therapy for metastatic prostate cancer showed no significant platelet activation. This bone-seeking radiopharmaceutical is safe regarding platelet function, even at therapeutic doses.

Area of Science:

Nuclear medicine
Oncology
Hematology

Background:

Metastatic prostate cancer often requires palliative treatment.
[153Sm] EDTMP is a bone-seeking radiopharmaceutical used for pain palliation.
Potential effects of radiopharmaceuticals on platelet function require investigation.

Purpose of the Study:

To evaluate the association between low-dose [153Sm] EDTMP therapy and platelet activation.
To assess the safety of [153Sm] EDTMP in patients with metastatic prostate cancer regarding hematological parameters.

Main Methods:

A single dose of 1.1 GBq [153Sm] EDTMP was administered to 29 patients with metastatic prostate cancer.
Platelet count and function parameters were monitored for 2 months post-administration.
Parameters included malondialdehyde levels, adenosine diphosphate-induced platelet aggregation, and platelet sensitivity.

More Related Videos

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Related Experiment Videos

Last Updated: Jul 19, 2026

In vitro Method to Observe E-selectin-mediated Interactions Between Prostate Circulating Tumor Cells Derived From Patients and Human Endothelial Cells

In vitro Method to Observe E-selectin-mediated Interactions Between Prostate Circulating Tumor Cells Derived From Patients and Human Endothelial Cells

Published on: May 15, 2014

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Main Results:

Transient, insignificant signs of platelet activation were observed 3 days post-therapy, rapidly normalizing.
Platelet aggregation response was temporarily reduced in non-count adjusted samples at nadir platelet count, but activity per cell remained unchanged.
No alterations in platelet proteins were detected, indicating no significant functional impact.

Conclusions:

A single dose of 1.1 GBq [153Sm] EDTMP does not significantly affect in vivo and ex vivo platelet function.
The observed mild platelet activation is likely due to transient oxidative stress and the temporary decrease in platelet count.
[153Sm] EDTMP therapy at the studied dose is considered safe concerning platelet behavior.